The critical role of alpha-synuclein in Parkinson's disease represents a pivotal discovery.
Some progress has been made over recent years in identifying disease-modifying therapies …

Synucleinopathies are neurodegenerative disorders characterized by alpha-synuclein
(αSyn) accumulation in neurons or glial cells, including Parkinson's disease (PD), dementia …

The circadian clock protein BMAL1 modulates glial activation and amyloid-beta deposition
in mice. However, the effects of BMAL1 on other aspects of neurodegenerative pathology …

Misfolding and aggregation of α-synuclein are specific features of Parkinson's disease and
other neurodegenerative diseases defined as synucleinopathies. Parkinson's disease …

The pathological hallmarks of Parkinson's disease (PD), a neurodegenerative disorder, are
the selective loss of dopamine neurons in the substantia nigra pars compacta (SNpc) and …

Pathology consisting of intracellular aggregates of alpha-Synuclein (α-Syn) spread through
the nervous system in a variety of neurodegenerative disorders including Parkinson's …

Parkinson's disease (PD) is a progressive neurodegenerative disease that impairs
movement as well as causing multiple other symptoms such as autonomic dysfunction, rapid …

Abstract Alpha-synuclein (a-syn) can aggregate and form toxic oligomers and insoluble
fibrils which are the main component of Lewy bodies. Intra-neuronal Lewy bodies are a …

The prodromal phase of Parkinson's disease is characterized by aggregation of the
misfolded pathogenic protein α-synuclein in select neural centres, co-occurring with non …

In patients affected by Parkinson's disease (PD), up to 50% of them experience cognitive
changes, and psychiatric disturbances, such as anxiety and depression, often precede the …